Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer

Area of Science:

• Oncology
• Computational Biology
• Pharmacology

Background:

• Combinatorial cancer therapy is crucial to overcome drug resistance from compensatory signaling pathways.
• Current drug combinations are limited, often based on empirical data, leaving vast therapeutic potential unexplored.

Purpose of the Study:

• To develop a computational network biology strategy for identifying novel synergistic drug combinations for breast cancer treatment.
• To discover drug pairs that inhibit pathway crosstalk, thereby enhancing antitumor efficacy.

Main Methods:

• Utilized in silico analysis based on pathway crosstalk inhibition to identify potential synergistic drug pairs.
• Screened 390 novel anticancer drug pairs across 10 drug classes.
• Experimentally validated 10 novel drug combinations in human breast cancer cell lines and a mouse model.

Main Results:

• Identified 390 potential synergistic drug pairs predicted to diminish pathway crosstalk.
• Seven of ten experimentally validated combinations demonstrated synergy in human breast cancer cell lines.
• The combination of raloxifene and cabozantinib showed dramatically enhanced antitumor effects in a preclinical breast cancer model.

Conclusions:

• The computational network biology approach effectively identifies novel synergistic drug combinations.
• This method significantly advances the discovery of broad-spectrum anticancer therapies compared to traditional high-throughput screening.
• Validated combinations, like raloxifene with cabozantinib, offer promising therapeutic strategies for breast cancer.